Clinical trials: Trifluridine and Tipiracil
Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma
Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer
Single-arm, open-label, multicenter phase 2 clinical trial evaluating the clinical and the immunological activity of an innovative strategy with an induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a…
- Conditions
- Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma, Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
- Trial name
- CombiCoR-Vax (NCT06522919)
- Testing
- Autologous Dendritic Cell (DC) Vaccine
- Where
- 2 sites in Italy
- Volunteers
- 36 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Metastatic Colorectal Cancer
Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients
Currently, the approved third-line treatments for metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine/tipiracil(TAS-102).
- Trial name
- NCT06403709
- Testing
- Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Metastatic Colorectal Cancer
Trifluridin/tipirACil in MeTastatIc Colorectal Cancer
A non-interventional, prospective, open, multicenter study in Germany in patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies and with…
- Trial name
- TACTIC (NCT03665506)
- Testing
- Trifluridin/Tipiracil
- Where
- Germany
- Volunteers
- 315 people
- Sponsor
- Servier
Cholangiocarcinoma, Bile Duct Cancer
Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma
This is a multi-centre, open-label, single arm phase 2 study to assess the efficacy of TRIFLURIDINE/TIPIRACIL, in patients with advanced cholangiocarcinoma as measured by median progression-free survival (PFS).
- Trial name
- MOCHA (NCT04076761)
- Testing
- Trifluridine/Tipiracil
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Sunnybrook Health Sciences Centre
Refractory Metastatic Colorectal Cancer
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
This study is designed as an international, open-label, controlled two-arm, randomized phase III comparison study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus…
- Trial name
- SUNLIGHT (NCT04737187)
- Testing
- Trifluridine/Tipiracil, Bevacizumab
- Where
- 99 sites in United States, Austria and 12 more
- Volunteers
- 492 people
- Sponsor
- Taiho Oncology, Inc.
Rectal Cancer
Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
The goal of this Phase 2 trial is to evaluate a neoadjuvant treatment mode for locally advanced rectal cancer (LARC), consisting of radiotherapy and concurrent Trifluridine/Tipiracil (TAS-102).
- Trial name
- TASLARC (NCT05965531)
- Testing
- Trifluridine/Tipiracil, intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Sun Yat-sen University
Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
This phase 1b trial studies the side effects and best dose of TAS-102 when given together with radiation therapy in treating patients with stage II-III rectal cancer that has not been treated and can be removed by surgery…
- Conditions
- Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Trial name
- NCT04104139
- Testing
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Trifluridine and Tipiracil Hydrochloride
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- OHSU Knight Cancer Institute
Metastatic Colorectal Cancer
CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer
HS-CA102N-103 is a Phase 2, randomized, open label study to evaluate efficacy, safety, and tolerability of CA102N combined with trifluridine/tipiracil (TAS-102) compared to bevacizumab combined with TAS-102 in subjects with…
- Trial name
- NCT06039202
- Testing
- CA102N, TAS-102, Bevacizumab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Holy Stone Healthcare Co., Ltd
Colorectal Cancer Metastatic, Chemotherapy
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
The current phase 2, double cohort clinical trial was designed to determine the effectiveness of Trifluridine and Tipiracil Hydrochloride Tablets, Bevacizumab and Sintilimab with/without involved lesions irradiation as 3rd- or…
- Conditions
- Colorectal Cancer Metastatic, Chemotherapy, Targeted Therapy, Immunotherapy
- Trial name
- NCT06764680
- Testing
- Trifluorouracil tepidopyrimidine, Bevacizumab, Sindilizumab
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer (CRC), Colorectal Cancer
Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer
Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with chemotherapy.
- Trial name
- NCT07286695
- Testing
- Fruquintinib Combined With trifluridine/tipiracil, Bevacizumab combined with trifluridine/tipiracil
- Where
- China
- Volunteers
- 292 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma
Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of trametinib and trifluridine and tipiracil hydrochloride in treating patients with colon or rectal cancer that has spread to other places in the body…
- Conditions
- Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Carcinoma, RAS Family Gene Mutation
- Trial name
- NCT03317119
- Testing
- Laboratory Biomarker Analysis, Trametinib, Trifluridine and Tipiracil Hydrochloride
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- City of Hope Medical Center
Metastatic Colorectal Cancer, Colorectal Cancer Metastatic
Sym004 Versus TAS-102 in Patients With mCRC
This is a Phase 3, randomized, open-label, 2-arm trial designed to evaluate overall survival (OS) following treatment with Sym004, an investigational medicinal product (IMP), versus TAS-102 (trifluridine/tipiracil), a comparator…
- Conditions
- Metastatic Colorectal Cancer, Colorectal Cancer Metastatic, Carcinoma
- Trial name
- NCT03717038
- Testing
- Sym004, TAS-102
- Sponsor
- Symphogen A/S
Metastatic Colorectal Adenocarcinoma
Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer
This study is a retrospective study to compare the efficacy and safety between trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) with TAS-102 monotherapy in refractory metastatic colorectal cancer (mCRC) from November 2020…
- Trial name
- NCT05869097
- Testing
- Trifluridine/Tipiracil, Bevacizumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hunan Cancer Hospital
Metastatic Colorectal Cancer
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
The goal of this single-arm study is to evaluate the efficacy and safety of Envafolimab combined with Trifluridine/Tipiracil and Bevacizumab in the treatment of metastatic colorectal cancer patients who are refractory or…
- Trial name
- NCT06060704
- Testing
- Envafolimab, Trifluridine/Tipiracil, Bevacizumab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Neoplasm, Chemotherapy Effect
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
This is a multicenter phase 2 study evaluating the efficacy and safety of trifluridine/tipiracil in women with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.
- Trial name
- TIBET (NCT04489173)
- Testing
- trifluridine/tipiracil
- Where
- 10 sites in Netherlands
- Volunteers
- 52 people
- Sponsor
- Borstkanker Onderzoek Groep
Metastatic Colorectal Cancer
A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy
The main purpose of this study is to evaluate the progression-free survival (PFS) in patients receiving S 95005 + bevacizumab (experimental arm) or capecitabine + bevacizumab (control arm) as first-line treatment for unresectable…
- Trial name
- TASCO1 (NCT02743221)
- Testing
- Trifluridine/tipiracil + bevacizumab, Capecitabine + bevacizumab
- Where
- 57 sites in Australia, Belgium and 10 more
- Volunteers
- 154 people
- Sponsor
- Institut de Recherches Internationales Servier
Metastatic Colorectal Cancer
Lonsurf® (Trifluridine/Tipiracil) Plus Chemotherapy in Metastatic Colorectal Cancer Prospective Study in Taiwan
Primary Endpoint : To evaluate the Disease control rate (DCR) Secondary Endpoints: To evaluate the Progression-free survival (PFS), Overall survival(OS) and Safety profile
- Trial name
- NCT06495463
- Testing
- Trifluridine/tipiracil
- Where
- Taiwan
- Volunteers
- 97 people
- Sponsor
- Chang Gung Memorial Hospital
Metastatic Colorectal Cancer
Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
FIRE-8 is a prospective, randomized, open label, multicenter phase II clinical trial. To evaluate the effecacy of trifluridine / tipiracil and panitumumab (Arm A) compared to trifluridine / tipiracil and bevacizumab (Arm B)…
- Trial name
- NCT05007132
- Testing
- Panitumumab 20 milligram/ML, Bevacizumab, Trifluridine/Tipiracil Hydrochloride
- Where
- Germany
- Volunteers
- 153 people
- Sponsor
- Dominik Paul Modest
Metastatic Colorectal Cancer
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of rivoceranib when used in combination with trifluridine/tipiracil in participants with mCRC and to assess progression-free survival (PFS) in…
- Trial name
- NCT04073615
- Testing
- Rivoceranib, Trifluridine/Tipiracil
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Elevar Therapeutics
Colorectal Cancer Metastatic
Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.
The aim oh this study is to determine the safety and recommended dose of trifluridine/tipiracil plus capecitabine and bevacizumab combination (part 1, dose escalation phase) and to assess its activity in previously untreated mCRC…
- Trial name
- TriComB (NCT04564898)
- Testing
- Capecitabine, Bevacizumab, Trifluridine/Tipiracil
- Where
- 2 sites in Italy
- Volunteers
- 48 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest